TRT optimization claims on TikTok: separating signal from hype

What did @coachdjvanillaface actually say?

The creator argues that women are increasingly using testosterone replacement therapy, and that telehealth clinics routinely start patients at 10mg per week, which they call "pretty serious" for female physiology. They push hard for injectable testosterone over pellets, citing serum stability, and warn that "many women are going to experience virilizing side effects as little as 3 milligrams per week." They also make the memorable point that clitoral enlargement and beard growth from androgenic exposure are not reversible once they occur. The overall message is: start low, advocate for yourself, and understand the side effects before you begin.

Worth noting upfront, the creator disclaims this is not promotion of performance-enhancing drugs and tells viewers to consult a physician. That framing matters because the actual clinical picture is more nuanced than the video lets on.

Does the science back this up?

Partially, yes. The concern about virilization at low doses is real, but the 3mg threshold they cite is presented as a universal rule, and the evidence is less clean than that.

The Endocrine Society's 2019 clinical practice guideline on androgen therapy in women acknowledges that testosterone in premenopausal and postmenopausal women can produce androgenic side effects, and recommends targeting physiological female reference ranges rather than male ones. Studies like Davis et al. (2019, The Lancet Diabetes and Endocrinology) support transdermal testosterone at doses producing serum levels in the normal female range for sexual dysfunction, but dose thresholds for virilization vary considerably between individuals based on androgen receptor sensitivity, baseline testosterone, and SHBG levels. The idea that 3mg is a hard floor for virilization in all women is an oversimplification.

On pellets vs. injectables, the pharmacokinetic critique has some merit. Pellets do produce supraphysiologic peaks shortly after insertion according to Glaser and Dimitrakakis (2013, Maturitas), but injectable testosterone cypionate or enanthate also produces peaks and troughs, especially with weekly dosing. The creator frames injectables as uniformly stable, which is not accurate without specifying injection frequency.

What did they get wrong (or right)?

They got the irreversibility point right. Clitoromegaly and hirsutism from androgen exposure can be permanent or only partially reversible after discontinuation. That is clinically documented and worth repeating loudly. Credit where it is due.

They got the telehealth caution directionally right too. Some direct-to-consumer hormone clinics do prioritize sales volume over conservative titration. That is a legitimate concern backed by reporting and by the absence of standardized female TRT dosing guidelines across platforms.

Where they went wrong: calling injectables "the most reliable route" without qualification. The evidence base for female testosterone therapy is actually strongest for transdermal formulations, specifically patches and gels, according to the 2019 global consensus position statement on testosterone therapy for women (Wierman et al., Journal of Clinical Endocrinology and Metabolism). Injectables in women are largely used off-label and carry their own pharmacokinetic variability depending on injection site and individual metabolism. The creator's preference may be practical, but presenting it as universally superior is not supported by current guidelines.

The claim that testosterone has a "one-to-one anabolic to androgenic ratio" is a bodybuilding heuristic, not a pharmacological measurement. It is a way of saying testosterone is both tissue-building and masculinizing, which is true, but the ratio framing is borrowed from anabolic steroid comparison charts, not endocrinology literature.

What should you actually know?

If you are a woman considering testosterone therapy, the most important thing is that there is no universally approved dose for female TRT in the United States. The FDA has not approved any testosterone product specifically for women, meaning all female TRT is off-label. That does not make it illegitimate, but it does mean physician judgment and individualized monitoring matter more, not less.

Starting doses in research protocols for women typically target serum testosterone levels within the upper normal female physiological range, roughly 15 to 70 ng/dL depending on the lab. Whether 10mg weekly gets you there depends on your baseline, your SHBG, your injection frequency, and the formulation. Some women will stay well within range; others will not. The creator's point about advocating for a lower starting dose and titrating up is sound clinical reasoning, even if the specific numbers they cite are not universally validated.

Monitoring blood work at baseline, 6 to 8 weeks after initiation, and every 3 to 6 months thereafter is standard practice in evidence-based protocols. If your provider is not ordering labs, that is a red flag regardless of what platform you are using.